Align Technology, Inc. (NASDAQ:ALGN) Director Joseph Lacob sold 29,724 shares of the company’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $260.91, for a total transaction of $7,755,288.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Align Technology, Inc. (NASDAQ ALGN) traded down $6.81 during trading on Friday, hitting $254.07. 1,355,083 shares of the stock were exchanged, compared to its average volume of 1,005,909. Align Technology, Inc. has a one year low of $88.56 and a one year high of $266.41. The firm has a market cap of $20,370.00, a P/E ratio of 78.18, a price-to-earnings-growth ratio of 2.52 and a beta of 1.41.
Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $1.01 EPS for the quarter, topping the Zacks’ consensus estimate of $0.82 by $0.19. Align Technology had a net margin of 19.98% and a return on equity of 25.60%. The company had revenue of $385.30 million during the quarter, compared to the consensus estimate of $359.80 million. During the same period in the prior year, the business posted $0.63 EPS. The company’s quarterly revenue was up 38.3% on a year-over-year basis. research analysts expect that Align Technology, Inc. will post 3.62 earnings per share for the current year.
A number of equities analysts recently weighed in on ALGN shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $205.00 target price (up from $200.00) on shares of Align Technology in a research note on Monday, August 7th. Zacks Investment Research lowered shares of Align Technology from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 21st. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $200.00 target price on shares of Align Technology in a research note on Monday, September 11th. Robert W. Baird reaffirmed a “buy” rating on shares of Align Technology in a research note on Tuesday, September 12th. Finally, Goldman Sachs Group upped their target price on shares of Align Technology from $185.00 to $210.00 and gave the stock a “buy” rating in a research note on Friday, September 15th. Eleven research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $235.55.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/01/align-technology-inc-algn-director-sells-7755288-84-in-stock.html.
About Align Technology
Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.
Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.